<DOC>
	<DOCNO>NCT01980030</DOCNO>
	<brief_summary>This Phase I/II multicenter study aim assess toxicity profile Romiplostim patient transfusion-dependent thrombocytopenia allogeneic HSCT . A total 24 patient transfusion-dependent thrombocytopenia allogeneic HSCT include . The main endpoint incidence severity adverse event .</brief_summary>
	<brief_title>Using ROMIPLOSTINE Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>Subjects must ≥ 18 year , willing able sign inform consent Patients could transplant hematological disorder ( malignant nonmalignant ) except myelodysplastic syndrome patient receive either myeloablative reduce intensity conditioning . All source allogeneic stem cell allow . Prolonged ( &gt; 2 month ) transfusiondependent thrombocytopenia Screenings mean platelet count≤ 20 x giga/L screening mean platelet count ≤ 50 x giga/L history bleeding . ( ECOG ) performance status 02 Adequate liver function Serum creatinine ≤ 176.8 μmol/L Bone marrow aspirate cytogenetics within 6 day first dose romiplostim Written inform consent Relapse/progression hematological malignancy ( marrow examination require ) Noncontrolled acute and/or chronic graft versus host disease ( GvHD ) Active uncontrolled infection Cardiac pathology Thrombosis Pregnancy breast feed Received interleukin11 ( IL11 ) within 4 week screen previously receive thrombopoietic growth factor Patients anticoagulant therapy Receipt plan receipt Pegylated Granulocyte Colony Stimulating Factor ( PEGGCSF ) , Granulocyte macrophagecolony stimulate factor ( GMCSF ) within 4 week first dose investigational product Subject use adequate contraceptive precaution , judgment investigator Sensitivity Escherichia coliderived product Inability comply study procedure . Subject currently enrol yet complete 30 day since end investigational device drug study No medical insurance French Health system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>